Sanofi, one of the largest pharmaceutical companies in the world, is an undisputed pillar in the field of global health. With a presence in over 100 countries, Sanofi employs nearly 100,000 people worldwide and is dedicated to improving people's lives by developing innovative treatments for various diseases, including rare diseases, multiple sclerosis, cancer, diabetes, and cardiovascular diseases. Its headquarters are located in Paris, and the company continues to grow thanks to its numerous production sites and research and development centers spread across the globe.
Sanofi is widely recognized for its major contributions in the health sector, particularly for the development of vaccines and therapies for rare and autoimmune diseases. The company is also at the forefront in the fight against infectious diseases and has developed several innovative cancer treatments. Its commitment to innovation is illustrated by its massive investments in research and development, which allow it to maintain a diverse and constantly evolving product portfolio.
Sanofi has recently launched a number of initiatives to strengthen its role in digital health. In June 2022, the company announced the launch of the Accelerator, an internal digital accelerator located in Paris. This accelerator aims to transform medical practice through the use of digital technology, data, and artificial intelligence. In collaboration with partners like OpenAI, Sanofi also introduced Muse, an AI tool designed to optimize the patient recruitment process for clinical trials.
Furthermore, Sanofi has established a strategic partnership with the deeptech pharmaceutical start-up Aqemia to accelerate drug discovery using quantum physics and generative AI. This partnership aims to discover small molecule drugs in various therapeutic areas, illustrating Sanofi's ongoing commitment to integrating cutting-edge technologies into its research activities.
Sanofi is increasingly positioning itself as a leader in the integration of artificial intelligence in the pharmaceutical sector. The company has invested in several strategic collaborations with start-ups and tech companies to harness the potential of AI in drug discovery. Through collaborations with Insilico Medicine and Owkin, Sanofi uses AI to optimize clinical trials and accelerate the development of new therapies, particularly in the field of oncology.
Sanofi recently participated in the VivaTech 2025 event, where it co-hosted discussions on scientific sovereignty in AI in collaboration with Nvidia. The company continues to be a key player in discussions on the digital transformation of the health sector. Additionally, Sanofi is involved in the Healthcare Data Institute, a think tank dedicated to maximizing the value of health data. Under the presidency of Christian Deleuze, Deputy General Manager for Innovation at Sanofi France, the HDI explores crucial issues regarding health data sovereignty.
Finally, Sanofi's commitment to digital innovation continues with its active participation in Future4Care, a start-up accelerator dedicated to digital health, created in partnership with Capgemini, Generali, and Orange. This initiative aims to support the development of digital health solutions in Europe, thereby strengthening Sanofi's position as a leader in the digital health ecosystem.
In summary, Sanofi continues to play a central role in global pharmaceutical innovation. Thanks to its commitment to integrating cutting-edge technologies, the company is well-positioned to tackle future challenges and continue improving global health.
23 articles liés à cet acteur
Follow VT News, the official VivaTech channel to not miss anything from this 2025 edition: What will happen at VivaTech on this 2nd day? The day will...
Cathay Innovation, a venture capital firm, has closed its third AI-dedicated fund, Fund III, with $1 billion. The fund aims to support the transformat...
VivaTech, the largest startup and tech event in Europe, offers an immersion into innovation with conferences from industry leaders and a showcase of p...
Insilico Medicine, an AI-based clinical-stage drug discovery company, announced a multi-year, multi-targeted strategic research collaboration with San...
The Institut Montaigne, the Abeona Foundation and Open Classrooms had joined forces to offer an online training program in French: Objectif IA. They h...
Aqemia announced on October 19 that it had raised €30 million in a Series A financing round co-led by Eurazeo and Bpifrance via its Large Venture fund...
According to the online journal Pharmaceutical Technology, machine learning engineers are increasingly sought after by pharmaceutical companies. The l...
On June 8, Owkin, a French-American start-up specializing in AI and federated learning applied to medical research, announced that it had entered into...
In early June, Sanofi Pharmaceuticals, whose ambition is to be a leader in digital health, announced the launch of Accelerator, an internal digital ga...
As part of the French Presidency of the Council of the European Union, the Direction Générale des Entreprises (DGE) is organizing, with the support of...
On June 10, 2021, Sanofi, Capgemini, Generali and Orange announced the creation of Future4care, which aims to accelerate the development of European e...
The objective of AIOLOS, a real-time multi-source data collection platform based on AI and predictive modeling, is to detect an epidemic linked to a r...
